Related Experiment Video
Updated: Jan 30, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
Published on: August 9, 2013
Targeting CDC42 Protects Mitochondrial Function through KLF2/HIF-1α/PINK1 Signaling in Acute Kidney Injury
Xue Zhou1,2,3, Xian Fu2,3, Yi-Wen Meng2,3
1Medical Examination Centre of the First Affiliated Hospital and CNTTI of College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Abstract:
Acute kidney injury (AKI) is a severe clinical syndrome strongly associated with mitochondrial dysfunction and oxidative stress, yet effective therapies remain elusive. Here, we identify cell division cycle 42 (CDC42) as a critical mediator of AKI. Analysis of human single-cell RNA sequencing (scRNA-seq) dataset revealed marked upregulation of CDC42 in renal tubular epithelial cells (RTECs), which was validated in murine models of cisplatin- and ischemia-reperfusion-induced AKI. Pharmacological inhibition, conditional knockdown, or genetic ablation of CDC42 significantly alleviated renal injury, preserved mitochondrial function, and reduced reactive oxygen species (ROS) both in vivo and in vitro. Mechanistically, transcriptomic analysis, bioinformatic analysis, dual-luciferase reporter assays, ChIP assays and cellular functional validation revealed that CDC42 suppression activated a KLF2/HIF-1α/PINK1 transcriptional cascade, thereby promoting mitophagy and restoring mitochondrial homeostasis. Functional assays supported that this pathway plays a pivotal role in protecting RTECs from oxidative damage. Collectively, these findings uncover a previously unrecognized role of CDC42 in AKI pathogenesis and highlight CDC42 inhibition as a promising therapeutic strategy for mitigating mitochondrial damage and improving renal outcomes.
Insights
Cell division cycle 42 (CDC42) drives acute kidney injury (AKI) by impairing mitochondrial function. Inhibiting CDC42 protects kidneys from damage and promotes recovery, offering a new therapeutic avenue for AKI.
Area of Science:
- Nephrology
- Molecular Biology
- Cell Biology
Background:
- Acute kidney injury (AKI) is a critical condition linked to mitochondrial dysfunction and oxidative stress.
- Current therapies for AKI are limited, necessitating novel treatment strategies.
Purpose of the Study:
- To investigate the role of cell division cycle 42 (CDC42) in the pathogenesis of AKI.
- To explore CDC42 inhibition as a potential therapeutic approach for AKI.
Main Methods:
- Analysis of human scRNA-seq data and murine AKI models (cisplatin, ischemia-reperfusion).
- Pharmacological inhibition, knockdown, and genetic ablation of CDC42.
- Transcriptomic analysis, bioinformatic analysis, dual-luciferase reporter assays, ChIP assays, and functional assays.
Main Results:
- CDC42 was significantly upregulated in renal tubular epithelial cells (RTECs) during AKI.
- CDC42 inhibition alleviated renal injury, preserved mitochondrial function, and reduced reactive oxygen species (ROS).
- CDC42 suppression activated a KLF2/HIF-1α/PINK1 cascade, promoting mitophagy and restoring mitochondrial homeostasis.
Conclusions:
- CDC42 is a critical mediator in AKI pathogenesis.
- Targeting CDC42 presents a promising therapeutic strategy for AKI by mitigating mitochondrial damage and improving renal outcomes.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention

